drug_type
RELEVANT_DRUG
intervention_type
cellular therapy (CAR T cells)
drug_description
Autologous chimeric antigen receptor T-cell therapy engineered to recognize BCMA (TNFRSF17) on malignant plasma cells and mediate targeted cytotoxic killing.
nci_thesaurus_concept_id
C176023
nci_thesaurus_definition
A preparation of CAR-T cells that targets the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA;TNFRSF17).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor specific for BCMA (TNFRSF17) on malignant plasma cells. Upon BCMA binding, CAR signaling (CD3ΞΆ with co-stimulatory domains) activates the T cells, driving proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BCMA-expressing cells.
drug_name
Anti-BCMA CAR-T cells
nct_id_drug_ref
NCT05979363